Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GSTCOTCMKTS:NRXGQOTCMKTS:OREXQNASDAQ:SMFL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSTCGlobeStar Therapeutics$0.00$0.00▼$0.00$124K1.953.11 million shsN/ANRXGQNephroGenex$0.00$0.00▼$0.21$36KN/A26,223 shs2,000 shsOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsSMFLSmart for Life$0.03+88.7%$0.01$0.00▼$3.98$178K1.384,721 shs8,583 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSTCGlobeStar Therapeutics0.00%0.00%0.00%-66.67%-83.33%NRXGQNephroGenex0.00%0.00%0.00%0.00%0.00%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%SMFLSmart for Life0.00%+104.62%-24.00%+101.52%-99.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSTCGlobeStar Therapeutics 0.00N/AN/AN/ANRXGQNephroGenex 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞SMFLSmart for Life$11.11M0.02N/AN/A($17.10) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSTCGlobeStar Therapeutics-$1.95MN/A0.00N/AN/AN/AN/A-3,176.19%N/ANRXGQNephroGenexN/AN/A0.00N/AN/AN/AN/AN/AN/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/ASMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/ALatest NRXGQ, GSTC, OREXQ, and SMFL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q2 2024SMFLSmart for LifeN/A-$2.41N/A-$2.34N/A$0.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSTCGlobeStar TherapeuticsN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSTCGlobeStar TherapeuticsN/A0.050.05NRXGQNephroGenexN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/ASMFLSmart for LifeN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSTCGlobeStar Therapeutics0.01%NRXGQNephroGenexN/AOREXQOrexigen TherapeuticsN/ASMFLSmart for Life28.39%Insider OwnershipCompanyInsider OwnershipGSTCGlobeStar Therapeutics2.50%NRXGQNephroGenexN/AOREXQOrexigen Therapeutics13.30%SMFLSmart for Life31.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSTCGlobeStar Therapeutics11.24 billion1.21 billionNot OptionableNRXGQNephroGenex1,70012.95 millionN/ANot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionableSMFLSmart for Life1107.09 million4.84 millionNot OptionableNRXGQ, GSTC, OREXQ, and SMFL HeadlinesRecent News About These CompaniesSmart for Life Inc. (SMFL) Analyst ResearchMarch 21, 2025 | nasdaq.comHere’s How ‘Smart Cities’ Focus On Resilience And Growth No Matter Who’s PresidentNovember 14, 2024 | forbes.comSMART High School Common App WorkshopOctober 26, 2024 | volunteermatch.org7 Smart Tips for Living a Joyful and Purpose-Driven LifeOctober 4, 2024 | fingerlakes1.comLucky for Life prize worth $25K a year for life won for 3rd time in a weekSeptember 30, 2024 | mlive.comMaximize Your Products' Lifespan with These Smart TricksSeptember 29, 2024 | msn.comSmart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring EffortsSeptember 23, 2024 | globenewswire.comSmart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full ComplianceSeptember 20, 2024 | globenewswire.comEufy’s Matter-enabled smart lock is 30% off todaySeptember 19, 2024 | msn.comSmart for Life Inc (SMFL) Stock Price Reaches $0.78: What Factors Are Influencing This Level?September 19, 2024 | bovnews.comEufy’s new smart lock may Matter to Apple Home usersSeptember 18, 2024 | msn.comSmart supramolecular assembliesSeptember 18, 2024 | sciencedaily.comLIFX A21 SuperColor Smart Light review: Affordable Hue alternativeSeptember 16, 2024 | yahoo.comEufy’s new smart lock is the company’s first with Matter supportSeptember 16, 2024 | msn.comSmart Homes for the Elderly: Making Life Easier and SaferSeptember 16, 2024 | msn.comSmart for Life Inc (SMFL) Stock: More Resilient Than It AppearsSeptember 13, 2024 | bovnews.comInsider Buying: Smart for Life, Inc. (NASDAQ:SMFL) Major Shareholder Buys 17,722 Shares of StockSeptember 12, 2024 | insidertrades.comHRT Financial LP Acquires New Stake in Smart for Life IncSeptember 12, 2024 | finance.yahoo.comSmart For Life Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9, 2024 | markets.businessinsider.comSmart for Life Inc (SMFL) Stock: Surpassing Expectations in the MarketSeptember 2, 2024 | bovnews.comMedia Sentiment Over TimeNRXGQ, GSTC, OREXQ, and SMFL Company DescriptionsGlobeStar Therapeutics OTCMKTS:GSTCGlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.NephroGenex OTCMKTS:NRXGQNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Smart for Life NASDAQ:SMFL$0.03 +0.01 (+88.72%) As of 03:56 PM EasternSmart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
